UBS Group
FLNA

UBS Group’s Filana Therapeutics FLNA Stock Holding History

UBS Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,000
Closed -$2.51M – 11084
2022
Q3 		$2.51M Buy
+60,000
New +$1.62M ﹤0.01% 2961
2021
Q4 		– Sell
-10,000
Closed -$621K – 10642
2021
Q3 		$621K Buy
+10,000
New +$835K ﹤0.01% 4573

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group's FLNA Position: Q1 2026 in Review

UBS Group reduced its Filana Therapeutics (FLNA) stake by 61% in Q1 2026, selling an estimated $37.6K and leaving 11,603 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7949.

UBS Group first reported a position in FLNA in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.62M in Q3 2024. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • UBS Group held 11,603 shares of Filana Therapeutics worth $19.6K as of Q1 2026.
  • UBS Group sold 18,266 Filana Therapeutics shares in Q1 2026, an estimated $37.6K.
  • Filana Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7949 holding.
  • UBS Group first reported a position in Filana Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Filana Therapeutics position peaked at $2.62M in Q3 2024.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.